Literature DB >> 28819022

β-Adrenergic Signaling in Mice Housed at Standard Temperatures Suppresses an Effector Phenotype in CD8+ T Cells and Undermines Checkpoint Inhibitor Therapy.

Mark J Bucsek1, Guanxi Qiao1, Cameron R MacDonald1, Thejaswini Giridharan1, Lauren Evans1, Brian Niedzwecki1, Haichao Liu1, Kathleen M Kokolus1, Jason W-L Eng1, Michelle N Messmer1, Kristopher Attwood2, Scott I Abrams1, Bonnie L Hylander1, Elizabeth A Repasky3.   

Abstract

The immune context of tumors has significant prognostic value and is predictive of responsiveness to several forms of therapy, including immunotherapy. We report here that CD8+ T-cell frequency and functional orientation within the tumor microenvironment is regulated by β2-adrenergic receptor (β-AR) signaling in host immune cells. We used three strategies-physiologic (manipulation of ambient thermal environment), pharmacologic (β-blockers), and genetic (β2-AR knockout mice) to reduce adrenergic stress signaling in two widely studied preclinical mouse tumor models. Reducing β-AR signaling facilitated conversion of tumors to an immunologically active tumor microenvironment with increased intratumoral frequency of CD8+ T cells with an effector phenotype and decreased expression of programmed death receptor-1 (PD-1), in addition to an elevated effector CD8+ T-cell to CD4+ regulatory T-cell ratio (IFNγ+CD8+:Treg). Moreover, this conversion significantly increased the efficacy of anti-PD-1 checkpoint blockade. These data highlight the potential of adrenergic stress and norepinephrine-driven β-AR signaling to regulate the immune status of the tumor microenvironment and support the strategic use of clinically available β-blockers in patients to improve responses to immunotherapy. Cancer Res; 77(20); 5639-51. ©2017 AACR. ©2017 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28819022      PMCID: PMC5645237          DOI: 10.1158/0008-5472.CAN-17-0546

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  48 in total

Review 1.  Highlights on immune checkpoint inhibitors in non-small cell lung cancer.

Authors:  Meng Shen; Xiubao Ren
Journal:  Tumour Biol       Date:  2017-03

Review 2.  Molecular pathways: beta-adrenergic signaling in cancer.

Authors:  Steven W Cole; Anil K Sood
Journal:  Clin Cancer Res       Date:  2011-12-20       Impact factor: 12.531

3.  Immunogenic Chemotherapy Sensitizes Tumors to Checkpoint Blockade Therapy.

Authors:  Christina Pfirschke; Camilla Engblom; Steffen Rickelt; Virna Cortez-Retamozo; Christopher Garris; Ferdinando Pucci; Takahiro Yamazaki; Vichnou Poirier-Colame; Andita Newton; Younes Redouane; Yi-Jang Lin; Gregory Wojtkiewicz; Yoshiko Iwamoto; Mari Mino-Kenudson; Tiffany G Huynh; Richard O Hynes; Gordon J Freeman; Guido Kroemer; Laurence Zitvogel; Ralph Weissleder; Mikael J Pittet
Journal:  Immunity       Date:  2016-02-09       Impact factor: 31.745

4.  A Threshold Level of Intratumor CD8+ T-cell PD1 Expression Dictates Therapeutic Response to Anti-PD1.

Authors:  Shin Foong Ngiow; Arabella Young; Nicolas Jacquelot; Takahiro Yamazaki; David Enot; Laurence Zitvogel; Mark J Smyth
Journal:  Cancer Res       Date:  2015-07-24       Impact factor: 12.701

5.  Safety, activity, and immune correlates of anti-PD-1 antibody in cancer.

Authors:  Suzanne L Topalian; F Stephen Hodi; Julie R Brahmer; Scott N Gettinger; David C Smith; David F McDermott; John D Powderly; Richard D Carvajal; Jeffrey A Sosman; Michael B Atkins; Philip D Leming; David R Spigel; Scott J Antonia; Leora Horn; Charles G Drake; Drew M Pardoll; Lieping Chen; William H Sharfman; Robert A Anders; Janis M Taube; Tracee L McMiller; Haiying Xu; Alan J Korman; Maria Jure-Kunkel; Shruti Agrawal; Daniel McDonald; Georgia D Kollia; Ashok Gupta; Jon M Wigginton; Mario Sznol
Journal:  N Engl J Med       Date:  2012-06-02       Impact factor: 91.245

6.  PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors.

Authors:  Michael A Curran; Welby Montalvo; Hideo Yagita; James P Allison
Journal:  Proc Natl Acad Sci U S A       Date:  2010-02-16       Impact factor: 11.205

Review 7.  Immune infiltration in human tumors: a prognostic factor that should not be ignored.

Authors:  F Pagès; J Galon; M-C Dieu-Nosjean; E Tartour; C Sautès-Fridman; W-H Fridman
Journal:  Oncogene       Date:  2009-11-30       Impact factor: 9.867

Review 8.  Ecoimmunology for psychoneuroimmunologists: Considering context in neuroendocrine-immune-behavior interactions.

Authors:  Gregory E Demas; Elizabeth D Carlton
Journal:  Brain Behav Immun       Date:  2014-09-10       Impact factor: 7.217

9.  Sympathetic neural signaling via the β2-adrenergic receptor suppresses T-cell receptor-mediated human and mouse CD8(+) T-cell effector function.

Authors:  Leonardo D Estrada; Didem Ağaç; J David Farrar
Journal:  Eur J Immunol       Date:  2016-06-08       Impact factor: 5.532

Review 10.  A nervous tumor microenvironment: the impact of adrenergic stress on cancer cells, immunosuppression, and immunotherapeutic response.

Authors:  Jason W-L Eng; Kathleen M Kokolus; Chelsey B Reed; Bonnie L Hylander; Wen W Ma; Elizabeth A Repasky
Journal:  Cancer Immunol Immunother       Date:  2014-10-12       Impact factor: 6.968

View more
  71 in total

1.  Schweinfurthin natural products induce regression of murine melanoma and pair with anti-PD-1 therapy to facilitate durable tumor immunity.

Authors:  Kathleen M Kokolus; Jeremy S Haley; Emily J Koubek; Raghavendra Gowda; Saketh S Dinavahi; Arati Sharma; David F Claxton; Klaus F Helm; Joseph J Drabick; Gavin P Robertson; Jeffrey D Neighbors; Raymond J Hohl; Todd D Schell
Journal:  Oncoimmunology       Date:  2018-11-11       Impact factor: 8.110

Review 2.  The Role of β-Blockers in Melanoma.

Authors:  Vincenzo De Giorgi; Pierangelo Geppetti; Chiara Lupi; Silvia Benemei
Journal:  J Neuroimmune Pharmacol       Date:  2019-09-03       Impact factor: 4.147

3.  The interplay among psychological distress, the immune system, and brain tumor patient outcomes.

Authors:  Sebastian Otto-Meyer; Jan Lumibao; Eugene Kim; Erik Ladomersky; Lijie Zhai; Kristen L Lauing; Denise M Scholtens; Frank Penedo; Christina Amidei; Rimas V Lukas; Derek A Wainwright
Journal:  Curr Opin Behav Sci       Date:  2019-02-26

4.  Beta blocker use correlates with better overall survival in metastatic melanoma patients and improves the efficacy of immunotherapies in mice.

Authors:  Kathleen M Kokolus; Ying Zhang; Jeffrey M Sivik; Carla Schmeck; Junjia Zhu; Elizabeth A Repasky; Joseph J Drabick; Todd D Schell
Journal:  Oncoimmunology       Date:  2017-12-21       Impact factor: 8.110

5.  Impact of concomitant medication use and immune-related adverse events on response to immune checkpoint inhibitors.

Authors:  Shipra Gandhi; Manu Pandey; Nischala Ammannagari; Chong Wang; Mark J Bucsek; Lamya Hamad; Elizabeth Repasky; Marc S Ernstoff
Journal:  Immunotherapy       Date:  2020-02-17       Impact factor: 4.196

Review 6.  Unintended Effects of GPCR-Targeted Drugs on the Cancer Phenotype.

Authors:  Abigail C Cornwell; Michael E Feigin
Journal:  Trends Pharmacol Sci       Date:  2020-10-22       Impact factor: 14.819

Review 7.  Sympathetic and parasympathetic innervation in cancer: therapeutic implications.

Authors:  Atsunori Kamiya; Takeshi Hiyama; Atsushi Fujimura; Soichiro Yoshikawa
Journal:  Clin Auton Res       Date:  2020-09-14       Impact factor: 4.435

Review 8.  Nerves in cancer.

Authors:  Ali H Zahalka; Paul S Frenette
Journal:  Nat Rev Cancer       Date:  2020-01-23       Impact factor: 60.716

9.  Stress-induced Norepinephrine Downregulates CCL2 in Macrophages to Suppress Tumor Growth in a Model of Malignant Melanoma.

Authors:  Kayla J Steinberger; Michael T Bailey; Amy C Gross; Laura A Sumner; Jeffrey L Voorhees; Nisha Crouser; Jennifer M Curry; Yijie Wang; A Courtney DeVries; Clay B Marsh; Ronald Glaser; Eric V Yang; Timothy D Eubank
Journal:  Cancer Prev Res (Phila)       Date:  2020-06-09

Review 10.  β-Adrenergic Signaling in Lung Cancer: A Potential Role for Beta-Blockers.

Authors:  Monique B Nilsson; Xiuning Le; John V Heymach
Journal:  J Neuroimmune Pharmacol       Date:  2019-12-11       Impact factor: 4.147

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.